Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 5:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1993–2016 of 6,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: Smoking
Interventions: Repetitive transcranial magnetic stimulation, MagStim Rapid2, Sham repetitive transcranial magnetic stimulation; Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Parkinson Disease
Interventions: e-Tapper TT-R1; Device
Lead sponsor: Boston University; Other
Eligibility: 50 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Crohn Disease
Interventions: Sample Collection; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 178 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Electrocardiogram
Interventions: Electrocardiogram; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Stanford, California

Conditions: Lupus Erythematosus, Systemic, Lupus Nephritis
Interventions: CTLA4-IgG4m (RG2077), Cyclophosphamide; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 2
States / cities: San Francisco, California • New York, New York

Conditions: Spine Fusion, Spine Tumor, Spinal Stenosis
Interventions: Ketamine; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 100 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy Participants
Interventions: Deucravacitinib, Famotidine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Miami, Florida • Austin, Texas

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Tysabri; Drug
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 64 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Metastatic Hepatocellular Carcinoma, Solid Tumors, Solid Tumor, Adult, FGFR Gene Amplification, FGFR Gene Alterations, Advanced Solid Tumors, FGFR4 Gene Mutation, FGFR4 Gene Fusions, FGF19 Gene Amplification, FGF19 Gene Overexpression, Locally Advanced Unresectable Hepatocellular Carcinoma
Interventions: TYRA-430; Drug
Lead sponsor: Tyra Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 9
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 6 more

Conditions: Carcinoma of Intrahepatic and Extra-hepatic Biliary System, Carcinoma of Gallbladder, Bile Duct Cancer, Cholangiocarcinoma
Interventions: DKN-01, gemcitabine, cisplatin; Drug
Lead sponsor: Leap Therapeutics, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 9
States / cities: Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 3 more

Conditions: Pancreatic Adenocarcinoma Metastatic
Interventions: OMTX705, Nab-paclitaxel + Gemcitabine, Tislelizumab (i.v. 200mg); Drug
Lead sponsor: Oncomatryx Biopharma S.L.; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bipolar Disorder, Schizophrenia
Interventions: Seroquel IR 300mg, Seroquel IR 25mg, Quetiapine Formulation A 300mg, Quetiapine Formulation B 300mg, Quetiapine Formulation 25mg; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Impact of Supervision on Endoscopy Simulation Curriculum
Interventions: Supervision/Coaching; Behavioral
Lead sponsor: University of Oklahoma; Other
Eligibility: 22 Years to 50 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Prostate Cancer
Interventions: Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) imaging; Procedure
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Male only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 3
States / cities: Bethesda, Maryland • New York, New York • Madison, Wisconsin

Conditions: SARS-CoV-2
Interventions: mRNA-1273, Placebo, mRNA-1273.222; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 12 Years to 18 Years
Enrollment: 4,328 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 48
States / cities: Banning, California • La Mesa, California • Lake Worth, Florida + 41 more

Conditions: Covid19
Interventions: Not listed
Lead sponsor: Tulane University; Other
Eligibility: 6 Months to 120 Years
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: New Orleans, Louisiana

Conditions: Hemianopia, Hemianopsia, Peripheral Visual Field Defect, Blindness, Retinitis Pigmentosa, Glaucoma
Interventions: Collision warning device; Device
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Advanced Solid Tumors
Interventions: Paclitaxel, RO5509554; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 2
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: Hoarding Disorder
Interventions: RECLAIM: Reducing Clutter and Increasing Meaning, Sorting Practice; Behavioral
Lead sponsor: Mississippi State University; Other
Eligibility: 60 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Starkville, Mississippi

Conditions: Arthritis, Rheumatoid
Interventions: LY3009104, Placebo, Methotrexate; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 31
States / cities: Paradise Valley, Arizona • Peoria, Arizona • Covina, California + 28 more

Conditions: NSCLC
Interventions: BMS-986315, Nivolumab, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 5
States / cities: Glendale, California • Clermont, Florida • Orange City, Florida + 2 more

Conditions: Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
Interventions: TAS6417; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Henderson, Nevada • Las Vegas, Nevada • Canton, Ohio + 1 more

Conditions: HIV
Interventions: rilpivirine/cabotegravir; Drug
Lead sponsor: Whitman-Walker Institute; Government
Eligibility: 18 Years and older
Enrollment: 180 participants
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Conditions: Prostate Cancer
Interventions: pembrolizumab, Low dose prostate radiation, Radical Prostatectomy; Drug · Radiation · Procedure
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

Insular Inhibitory Neuromodulation to Reduce Cigarette Craving and Alter Brain Function in Smokers

Bio Electro Stimulation Therapy for Parkinson's Disease

Combinatorial Single Cell Strategies for a Crohn's Disease Gut Cell Atlas

Surface ECG Mapping

Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)

Effect of Ketamine on Intraoperative Motor Evoked Potentials

A Study to Evaluate the Drug Levels of Deucravacitinib From Tablets After Oral Administration in Healthy Participants

Examining Effects of Tysabri on Cognitive Fatigue Using fMRI

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder

Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma

Trial to Assess the Bioavailability of Quetiapine Versus Seroquel® in Subjects With Schizophrenia or Bipolar Disorder

Outcomes in Simulated Endoscopy Training

Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Microtubule Directed Chemo or AR-directed Therapy

A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19

Collection of SARS CoV-2 (COVID-19) Virus Secretions and Serum for Countermeasure Development

Collision Warning Device for Blind and Visually Impaired

A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors

Motivational Interviewing to Enhance Behavioral Change in Older Adults With Hoarding Disorder

A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy

A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

Clinical Effectiveness-Implementation Hybrid Type 2 Study on Home-Delivered Cabenuva for People Living With HIV Who Are Not Retained in Care

Trimodality Approach of Low Dose iOnizing Radiation With or Without Neoadjuvant Pembrolizumab and Prostatectomy for Men With Intermediate/High Risk Prostate Cancer (TALON)